Literature DB >> 11851731

Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions.

K R Aoki1, B Guyer.   

Abstract

Botulinum toxin type A is an important therapeutic agent for the treatment of movement and other disorders. As the clinical uses of botulinum toxin type A expand, it is increasingly important to understand the biochemical and pharmacological actions of this toxin, as well as those of other botulinum toxin serotypes (B-G). Botulinum neurotoxin serotypes exhibit differences in neurotoxin complex protein size, percentage of neurotoxin in the activated or nicked form, intracellular protein target, and potency. These properties differ even between preparations that contain the same botulinum toxin serotype due to variations in product formulations. As demonstrated in preclinical and clinical studies, these differences result in a unique combination of efficacy, duration of action, safety, and antigenic potential for each botulinum neurotoxin preparation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11851731     DOI: 10.1046/j.1468-1331.2001.00035.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  54 in total

1.  Molecular basis of activation of endopeptidase activity of botulinum neurotoxin type E.

Authors:  Roshan V Kukreja; Shashi K Sharma; Bal Ram Singh
Journal:  Biochemistry       Date:  2010-03-23       Impact factor: 3.162

Review 2.  [Botulinum toxin therapy in orthopaedics].

Authors:  L Döderlein
Journal:  Orthopade       Date:  2006-01       Impact factor: 1.087

3.  The role of exoproteases in governing intraneuronal metabolism of botulinum toxin.

Authors:  Lance L Simpson; Andrew B Maksymowych; Hirokazu Kouguchi; Garrett Dubois; Roop S Bora; Suresh Joshi
Journal:  Protein J       Date:  2005-04       Impact factor: 2.371

Review 4.  Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms.

Authors:  Catherine A Thomas; Yao-Chi Chuang; Antonella Giannantoni; Michael B Chancellor
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

5.  Use of botulinum toxin A in management of children with cerebral palsy.

Authors:  Bat-Chen Friedman; Ran D Goldman
Journal:  Can Fam Physician       Date:  2011-09       Impact factor: 3.275

6.  Novel Uses for Botulinum Neurotoxin in Upper Limb Surgery.

Authors:  C W Metcalfe; S Naji; P McArthur
Journal:  J Hand Microsurg       Date:  2014-09-13

Review 7.  The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals.

Authors:  Adi Lahiani; Ephraim Yavin; Philip Lazarovici
Journal:  Toxins (Basel)       Date:  2017-03-16       Impact factor: 4.546

Review 8.  Pharmacologic interventions for treating phantom limb pain.

Authors:  Maria Jenelyn M Alviar; Tom Hale; Monalisa Dungca
Journal:  Cochrane Database Syst Rev       Date:  2016-10-14

Review 9.  Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction.

Authors:  Koenraad De Boulle; Steven Fagien; Boris Sommer; Richard Glogau
Journal:  Clin Interv Aging       Date:  2010-04-26       Impact factor: 4.458

10.  Intrathecal baclofen pump for spasticity: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.